. Acute exposure to angiostatin or endostatin nearly abolished subsequent endothelial [Ca 2ϩ ]i responses to carbachol or to thapsigargin; conversely, thapsigargin attenuated the Ca 2ϩ signal elicited by endostatin. The phospholipase C inhibitor U-73122 and the inositol trisphosphate (IP 3) receptor inhibitor xestospongin C both inhibited endostatin-induced elevation in [Ca 2ϩ ]i, and endostatin rapidly elevated endothelial cell IP 3 levels. Pertussis toxin and SB-220025 modestly inhibited the endostatin-induced Ca 2ϩ signal. Removal of extracellular Ca 2ϩ inhibited the endostatin-induced rise in [Ca 2ϩ ]i, as did a subset of Ca 2ϩ -entry inhibitors. Peak Ca 2ϩ responses to endostatin and angiostatin in endothelial cells exceeded those in epithelial cells and were minimal in NIH/3T3 cells. Overnight pretreatment of endothelial cells with endostatin reduced the subsequent acute elevation in [Ca 2ϩ ]i in response to vascular endothelial growth factor or to fibroblast growth factor by ϳ70%. Intracellular Ca 2ϩ signaling may initiate or mediate some of the cellular actions of endostatin and angiostatin. intracellular calcium; fura 2; xestospongin C; inositol trisphosphate; vascular endothelial growth factor; fibroblast growth factor 2 ANGIOGENESIS, THE FORMATION of new blood capillaries from preexisting blood vessels, is a complex process required for organogenesis and embryonic development (3) . Angiogenesis is also required for tumors to grow beyond several millimeters in diameter (14, 37) and likely contributes to metastasis (49) . An extensive network of stimulators and inhibitors regulates angiogensis. Among the stimulators are potent endothelial cell mitogens such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2).
Inhibitors of angiogenesis have been embraced as antitumor agents due to their high degree of apparent specificity for endothelial cells (35, 36) , the absence of desensitization or resistance to their antiangiogenic effects (2) , their ability to potentiate radiation therapy (31) , and their apparently low systemic toxicity (2, 31, 37) . A number of angiogenesis inhibitors have been found to be particularly associated with the presence of tumors, including angiostatin (37) and endostatin (36) . Angiostatins comprise the first three, four, or five kringle domains of the plasminogen molecule (37) and are generated by matrix metalloprotease activity upregulated in and secreted by tumor-infiltrating macrophages (13) . Endostatin is a 20-kDa COOH-terminal fragment of collagen XVIII (36) of known crystal structure (20) , thought to be generated by a two-step process involving matrix metalloproteases and elastases (47) . Both angiostatin and endostatin can be found in the circulation of tumor-bearing individuals.
Different angiogenesis inhibitors appear to exert their most potent effects against cancers in distinct stages of malignant transformation (1) . Most published work on the biological effects of angiostatin and endostatin has focused on antitumor activity in vivo (2, 9, 31, 36, 37) and in vitro (10, 11, 27, 38) . Endostatin may inhibit endothelial cell migration and endothelial cell proliferation via G 1 arrest (9) , and angiostatin inhibits cell migration (6) . Both angiostatin and endostatin induce endothelial cell apoptosis (6, 10), but angiostatin, at least in some cells, does not inhibit DNA synthesis (6) . Only recently have more acute actions of angiogenesis inhibitors been investigated, but results have differed in different endothelial cell types. Thus prolonged angiostatin treatment has been shown to inhibit activation of the mitogen-activated protein kinases ERK1 and ERK2 by FGF-2 or by VEGF in human dermal microvascular cells (39) . In contrast, angiostatin pretreatment did not inhibit FGF-2-induced activation of p42 or p44 mitogen-activated protein kinase in bovine adrenal capillary endothelial cells (6) . However, angiostatin itself acutely enhanced ty-rosine phosphorylation of p125 focal adhesion kinase in both porcine aortic endothelial cells and mouse pancreatic endothelial cells independent of Arg-Gly-Asp (RGD) recognition by integrins (6) .
Angiostatin and endostatin have been postulated to exert their biological effects via cell surface receptors yet to be identified. Interactions have been proposed with circulating or matrix-bound signaling proteins such as heparan sulfate proteoglycans (20) . Prolonged exposure to endostatin attenuates acute Ca 2ϩ signaling in response to subsequent treatment with proangiogenic growth factors.
MATERIALS AND METHODS
Materials. Xestospongin C, SB-220025, PD-98059, SKF-96365 HCl, and pertussis toxin (PTX) were obtained from Calbiochem (La Jolla, CA). U-73122 was from Research Biochemicals (Natick, MA). Gadolinium trichloride (Gd 3ϩ ), tetraethylammonium chloride, nitrendipine, neomycin, clotrimazole, EGTA, thapsigargin, and carbachol were from Sigma Chemical (St. Louis, MO). 1,2-Bis(2-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetic acid-acetoxymethyl ester (BAPTA-AM) and fura 2-AM were from Molecular Probes (Eugene, OR). Human VEGF-165 and human basic FGF-2 were from R&D Systems (Minneapolis, MN). All other reagents were of the highest available grade.
Biosynthesis and purification of recombinant endostatin and angiostatin. Recombinant mouse endostatin (9, 11) was expressed in the methanotropic yeast Pichia pastoris (Invitrogen, San Diego, CA), purified by heparin-agarose and gel filtration chromatography, and characterized as previously described (9, 11) . Recombinant mouse angiostatin [357 amino acids containing kringle I-IV of plasminogen, relative molecular weight (M r) ϳ44 kDa with glycosylation] was cloned, expressed in P. pastoris, and purified on lysine-agarose chromatography as described (30) . Chemical purity was confirmed by mass spectroscopy.
Endostatin purified from P. pastoris in three separate inductions exhibited consistent activity in assays of cell proliferation, induction of apoptosis, and elevation of intracellu- of endostatin were diluted at least 500-fold in endotoxin-free diluent before use to yield final endostatin concentrations up to 2 g/ml. Thus working solutions of two endostatin preparations contained Յ6 pg/ml of endotoxin, whereas the third preparation contained Յ20 ng/ml of endotoxin. However, the three endostatin preparations did not differ in their Ca ]i elicited by all preparations of endostatin.
Endostatin produced from baculovirus-infected insect cells was from Calbiochem. Angiostatin was isolated from a single Pichia preparation and was diluted 200-fold from stock before use.
Neutralizing antibody to mouse endostatin. Purified endostatin produced in P. pastoris was used to raise rabbit antiserum that specifically recognized endostatin as previously described (9) . IgG was purified from this antiserum by protein A chromatography, stored at 3 mg/ml, and used at a final concentration of 0.3 M.
Cell lines. BAEC were harvested from descending thoracic aortas obtained from the local abattoir by collagenase digestion and used at passages 6-12 (gift of A. Malek) and at passages 4-10 (gift of C. Ferran). Calf pulmonary artery endothelial cells (CPAEC), COS-7 SV40 transformed African green monkey kidney cells, and HEK-293 human embryonic kidney cells were obtained from American Type Culture Collection (Rockville, MD). Human microvascular endothelial cells (HMVEC) were purchased from Clonetics (San Diego, CA). All cells were cultured in humidified incubators at 37°C in 5% CO 2. HMVEC were maintained in endothelial growth medium-2 containing various growth factors suggested by the manufacturer (Clonetics). All other cell lines were maintained in DMEM (GIBCO BRL) supplemented with 4 mM L-glutamine, 10 U/ml penicillin, and 10 g/ml streptomycin.
Measurement of [Ca 2ϩ ]i. Fluorescence ratio digital imaging of [Ca 2ϩ ]i was as described (23, 24, 26, 29, 30) , with modifications. Cells were grown to subconfluency on 25-mm coverslips in six-well plates (Corning-Costar, Cambridge, MA). In one experiment as noted, confluent cells were used. Coverslips were coated with 3.5 g/cm 2 Cell-Tak (Collaborative BioProducts, Bedford, MA) for HEK-293 and Cos-7 cells to improve adhesion. Cells on coverslips were incubated in medium containing 2 M fura 2-AM for 30-40 min. The coverslips were then washed three times in modified Hanks' balanced salt solution (HBSS), pH 7.4, containing (in mM) 127 NaCl, 5.6 KCl, 1.27 CaCl2, 1.0 MgCl2, 5.6 glucose, and 11.6 HEPES. Washed coverslips were mounted in a modified chamber positioned on the platform of an Olympus IMT-2 inverted microscope. To conserve recombinant antiangiogenic agents, in most experiments exchange of the 1-ml chamber volume was achieved by suction through an 18G 1 1 ⁄2-in. needle affixed to the chamber's bottom edge, with manual volume replacement within 5 s by pipetting from above. The manual bath exchange procedure (and its associ-ated mechanical stimulus to the cells) was identical for medium containing or lacking the antiangiogenic agents.
Image acquisition began within 10-15 s after solution change. In some experiments, BAEC were perfused with medium without or with endostatin at a constant rate of ϳ10 ml/min, with chamber volume set at 0.3 ml. [Ca 2ϩ ]i was measured in room air at room temperature by ratio imaging with the Image-1 digital ratio imaging system (Universal Imaging, Westchester, PA) equipped with a Dage-MTI CCD7 camera and a Geniisys image intensifier system. Fura 2 fluorescence images were acquired at 510-nm emission with alternate excitation at 340 and 380 nm at programmed intervals. F 340/F380 ratio images of individual cells calculated on a pixel-by-pixel basis were recorded to optical disks on a Pinnacle REO-650 optical disk drive for later data processing. The region of interest for each cell encompassed the entire cell projection area, including the nucleus.
The ratio values were calibrated in vitro to free Ca 2ϩ concentrations ranging from 0 to 39.8 M (Ca 2ϩ calibration buffer kit no. 2; Molecular Probes) using the same imaging parameters. Dissociation constant (Kd) was determined by fitting the experimental R value at various free Ca 2ϩ concentrations using the equation
, where the factor Sf2/Sb2 corrects for fura 2 ion sensitivity at 380 nm. A similar procedure was employed for in situ calibration, in which 2 M of 4-Br-A23187 (Molecular Probes), a nonfluorescent Ca 2ϩ ionophore, was used to ]i was allowed to stabilize before initiation of data acquisition. transients in fura 2-AM-loaded BAEC subjected to bath exchanges in the absence (unlabeled arrows) or presence of 2 g/ml endostatin (Endo). B: Ca 2ϩ transients in fura 2-AM-loaded BAEC subjected to bath exchanges in the absence (unlabeled arrows) or presence of 5 g/ml angiostatin (ANGI). C: BAEC first exposed to endostatin retain their response to angiostatin while sustaining desensitization to the mechanical stimulus of simple bath exchange. D: magnitude of peak BAEC Ca 2ϩ transients in response to increasing concentrations of endostatin, with K 1 ⁄2 value of 0.77 Ϯ 0.18 g/ml (n ϭ 3-4 coverslips; 9 for 2 g/ml), each with 15-30 cells analyzed. Standard deviations ranged from 13 to 23% of the mean at each endostatin concentration. [Ca 2ϩ ]i, intracellular Ca 2ϩ concentration.
Measurement of IP3. BAEC were grown to ϳ70% confluence in 12-well plates. Quiescent cells were extracted with perchloracetic acid (PCA). Cells were extracted again after five manual washes in HBSS, a protocol that desensitizes the cells to mechanical [Ca 2ϩ ]i transients (Fig. 1 ). Cells were then exposed to HBSS containing 2 g/ml of endostatin and subsequently PCA-extracted at the times indicated. IP3 concentrations in the BAEC PCA extracts were measured by a radioligand binding displacement assay kit (Biotrak; Amersham Pharmacia Biotech) according to the manufacturer's instructions. PCA-soluble protein concentration was measured by the bicinchoninic acid method (Pierce). Figs. 1 and 2) . Of 255 BAEC monitored on 17 coverslips, 82 Ϯ 9% exhibited these Ca 2ϩ transients, which desensitized after three or four consecutive 1-ml solution changes, as shown in Fig. 1A . Intracellular Ca 2ϩ transients triggered in CPAEC and in HMVEC by replacement of extracellular medium exhibited similar desensitization patterns and were abolished in cells preloaded with BAPTA-AM (not shown).
RESULTS

Desensitization of endothelial [
In all experiments to follow, antiangiogenic agents were added to cells only after desensitization of the mechanical stimulus-evoked [Ca 2ϩ ] i response by at least five solution changes in the absence of drug. Beyond Fig. 1 , only one or two of these Ն5 desensitizing solution changes before drug addition are shown.
[Ca 2ϩ ] i transients in BAEC induced by endostatin and angiostatin. After desensitization of subconfluent BAEC to the mechanical stimulus of manual bath exchange, the extracellular medium was replaced with buffer containing 2 g/ml endostatin (100 nM) or 5 g/ml angiostatin (120 nM). Within ϳ18-30 s, angiostatin and endostatin both elicited rapidly rising but transient elevations in [Ca 2ϩ ] i (Fig. 1, A-C ] i in subconfluent BAEC by 179 Ϯ 41 nM (mean Ϯ SD for first endostatin exposures on 9 coverslips, each with 12 endostatin-responsive cells imaged) and in confluent Fig. 2 . Endostatin and angiostatin deplete intracellular Ca 2ϩ stores but do not depend entirely on these stores for Ca 2ϩ signaling. A: after desensitization to bath exchange, BAEC exposed to 2 g/ml endostatin exhibited minimal response to 100 M carbachol (CRB) or to subsequently added 10 M thapsigargin (TG). B: if first exposed to CRB and to TG, BAEC retained responsiveness to endostatin. C: in the continued presence of 5 M TG, cells exhibited significant but diminished response to endostatin. D: after desensitization to bath exchange, BAEC first exposed to 2 g/ml angiostatin exhibited minimal response to subsequently added 100 M CRB or 10 M TG. E: in contrast, prior exposure to CRB and TG did not abolish BAEC responsiveness to angiostatin. F: in the continued presence of 5 M TG, cells exhibited significant but diminished response to angiostatin. Fig. 1, B and C) .
Endostatin elicited increases in [Ca 2ϩ ] i in a dosedependent manner, starting at concentrations as low as 0.1 g/ml (5 nM, Fig. 1D ) and exhibited a K 1 ⁄2 value of 0.77 Ϯ 0.18 g/ml. Endostatin (2 g/ml) produced by insect cells infected with recombinant baculovirus (Calbiochem) produced comparable elevation in [Ca 2ϩ ] i . Acute [Ca 2ϩ ] i increases in response to endostatin and angiostatin were absent in cells preloaded with BAPTA-AM (not shown).
To rule out the possibility that the Ca 2ϩ signals might be artifactual results of the manual solution change procedure, the response of BAEC to endostatin (2 g/ml) was also tested during continuous superfu- ] i elevation elicited by superfusion under identical conditions with the well-studied agonist, extracellular ATP (50 M), but smaller than that elicited by the agonist thrombin (0.5 U/ml; 319 Ϯ 18 nM over baseline; n ϭ 4 coverslips in each condition).
Endostatin and angiostatin deplete intracellular Ca 2ϩ stores responsive to carbachol and thapsigargin. BAEC acutely exposed to 2 g/ml endostatin ( Fig. 2A) or to 5 g/ml angiostatin (Fig. 2D ) no longer exhibited elevations in [Ca 2ϩ ] i in response to 100 M carbachol or to subsequently applied 10 M thapsigargin. In contrast, when BAEC were first exposed to carbachol and then thapsigargin, they retained the ability to exhibit Ca 2ϩ transients in response to subsequent application of endostatin (Fig. 2B) or angiostatin (Fig.  2E) . When BAEC were first treated with 5 M thapsigargin, leading to respective peak and steady-state [Ca 2ϩ ] i increases of 70 Ϯ 16 nM and 24 Ϯ 9 nM above the pre-thapsigargin level (Fig. 2, E and F; n ϭ 6 ), subsequent addition of 2 g/ml endostatin (Fig. 2E) or 5 g/ml angiostatin (Fig. 2F) in the continued presence of thapsigargin elicited further transient respective increases of 45 Ϯ 10 nM and 25 Ϯ 11 nM (n ϭ 3), which quickly relaxed to the thapsigargin baseline. These data show that endostatin and angiostatin share the ability to deplete thapsigargin-sensitive intracellular Ca 2ϩ stores normally released by muscarinic agonists. Moreover, endostatin and angiostatin retain partial ability to elevate [Ca 2ϩ ] i in cells with Ca 2ϩ stores previously depleted by thapsigargin.
Role of IP 3 in endostatin signaling. The above findings suggest a role for IP 3 signaling in the action of endostatin on BAEC. As shown in Fig. 3 , preincubation of BAEC with the IP 3 receptor (IP 3 R) inhibitor xestospongin C (22) at 2 or 10 M inhibited the subsequent endostatin-triggered peak [Ca 2ϩ ] i elevation of 140 Ϯ 13 nM by 61 and 76% to levels of 55 Ϯ 13 and 33 Ϯ 12 nM, respectively. In the absence of extracellular Ca 2ϩ , 10 M xestospongin C inhibited the peak endostatin response by 95%.
When xestospongin C was added to BAEC simultaneously with endostatin, xestospongin C was without effect. However, xestospongin C preincubations of 5-8 min (as in Fig. 3) were maximally effective. The effect of a 40-min preincubation with xestospongin C was reversed within 5 min following xestospongin C removal from the medium (not shown). Thus endostatin Ca 2ϩ signaling likely required IP 3 R-regulated intracellular Ca 2ϩ stores. IP 3 ] i signal by 50% to 92 Ϯ 13 nM (not shown).
As suggested by the inhibitory effects of U-73112 and xestospongin C, endostatin itself rapidly increased IP 3 levels in BAEC (Fig. 4B) . Resting cells had IP 3 content of 32 pmol/mg PCA-soluble protein (n ϭ 2), which increased to 95 Ϯ 16 pmol/mg (n ϭ 6) after the fivewash densitization protocol. Subsequent addition of endostatin (2 g/ml) further increased IP 3 levels to 135 Ϯ 15 pmol/mg after 10 s (P Ͻ 0.05) and to 174 Ϯ 14 pmol/mg after 20 s (P Ͻ 0.01). This elevation in IP 3 ] i elevation following endostatin and angiostatin exposure by 60% (n ϭ 4) and 59% (n ϭ 5), respectively (P Ͻ 0.01 for both conditions). Inhibition of [Ca 2ϩ ] i signaling was further enhanced when extracellular Ca 2ϩ removal was combined with inhibitors of intracellular targets. Thus when BAEC were treated with xestospongin C in Ca 2ϩ -free conditions, the endostatin-induced elevation in [Ca 2ϩ ] i was nearly completely abolished (Fig. 3B ). Because G proteins regulate some plasmalemmal Ca 2ϩ -entry pathways, a role for PTX-sensitive G proteins in endostatin Ca 2ϩ signaling was tested. As shown in Fig. 5 , a 1-h preincubation of BAEC with 1 M PTX inhibited the endostatin-and angiostatininduced Ca 2ϩ signals by 30 and 32%, respectively (n ϭ 4, P Ͻ 0.05). When extracellular Ca 2ϩ chelation was combined with PTX pretreatment of BAEC, peak [Ca 2ϩ ] i elevation following endostatin and angiostatin exposure was inhibited by 79 and 78%, respectively (n ϭ 4; P Ͻ 0.01 compared with bath Ca 2ϩ removal alone, P Ͻ 0.001 compared with control).
The mitogen-activated protein kinase pathway may regulate Ca 2ϩ signaling. As shown in Fig. 6 , inhibition of the endostatin-induced peak Ca 2ϩ elevation by the p38 kinase inhibitor SB-220025 (2 M) was modest (P ϭ 0.05). However, at the less specific concentration of 20 M, SB-220025 inhibited the peak Ca 2ϩ response by 71% (n ϭ 3, P Ͻ 0.001). In contrast, the mitogenactivated protein kinase or ERK1 inhibitor PD-98059 failed to significantly inhibit the endostatin-induced peak Ca 2ϩ response at either 2 or 20 M (n ϭ 3, P Ͼ 0.1). [Ca 2ϩ ] i elevation. Figure 7 shows that endostatin-induced [Ca 2ϩ ] i elevation in BAEC was not significantly inhibited by the L-type Ca ] i elevation by 70 and 58%, respectively (P Ͻ 0.05). Reduction in the driving force for Ca 2ϩ entry via membrane depolarization by the K ϩ channel blocker tetraethylammonium (2 mM) also inhibited intracellular Ca 2ϩ signal amplitude by 61% (P Ͻ 0.05). Endostatin and angiostatin elevate [Ca 2ϩ ] i preferentially in endothelial cells. Figure 8 shows that HMVEC exhibited the largest Ca 2ϩ transients in response to endostatin (Fig. 8A) and angiostatin (Fig. 8B) among We therefore tested the effect of overnight exposure of BAEC to 2 g/ml endostatin on the ability of both of these growth factors to elevate [Ca 2ϩ ] i . As shown in Fig. 9 , endostatin preincubation reduced peak [Ca 2ϩ ] i induced by 30 ng/ml VEGF-165 by 65% (Fig. 9, A and  C) , from 141 Ϯ 20 to 50 Ϯ 8 nM (n ϭ 5), and reduced peak [Ca 2ϩ ] i induced by 25 ng/ml FGF-2 by 71% (Fig. 9 , B and C), from 126 Ϯ 16 to 37 Ϯ 5 nM (n ϭ 5, each decrease significant at P Ͻ 0.001).
Effects of Ca 2ϩ entry inhibitors on endostatin-induced
DISCUSSION
Natural angiogenesis inhibitors such as angiostatin and endostatin have entered phase 1 clinical trials for cancer treatment (40) . Additional trials are planned for other disorders in which unregulated angiogenesis is believed to contribute to pathogenesis (8) . However, remarkably little remains known about the mechanisms of action of these proteolytic products of plasminogen and of the nonfibrillar collagen XVIII. We have shown here that angiostatin and endostatin acutely elevate [Ca 2ϩ ] i in primary cultures of bovine and human endothelial cells grown on coverslips. The elevation in cytoplasmic [Ca 2ϩ ] i arose from a combination of Ca 2ϩ release from IP 3 -sensitive intracellular stores and from activation of an extracellular Ca 2ϩ -entry pathway. The [Ca 2ϩ ] i elevation appeared to be regulated by a PTX-sensitive G protein and by an SB-220025-sensitive process that may be a kinase activity. The Ca 2ϩ transients were of considerably greater magnitude in endothelial than in nonendothelial cells tested. Endostatin elevated [Ca 2ϩ ] i in BAEC at concentrations of 100 ng/ml (5 nM) and above, higher than required for inhibition of endothelial cell migration (48) (Fig. 1D) . However, endostatin concentrations in this range, which have been achieved by adenovirus-mediated gene transfer in intact mice (41) , can inhibit endothelial cell proliferation and induce apoptosis in vivo and in cell culture (10, 11, 13) . Ca 2ϩ signaling by endostatin exhibited specificity by several additional criteria. Contaminating endotoxin was not responsible for the elevation in [Ca 2ϩ ] i . In most preparations, endotoxin was present at 6 pg/ml, and purified LPS at this concentration is inactive. One less pure preparation contained 20 ng/ml endotoxin, but nonetheless exhibited indistinguishable Ca 2ϩ -signaling properties. Consistent with this observation and with earlier studies (46), 20 pg/ml of purified LPS elicited a Ca 2ϩ signal Ͻ10% the magnitude of that elicited by endostatin. In addition, Ca 2ϩ transients were higher in endotoxin-resistant HMVEC than in endotoxin-sensitive CPAEC. Moreover, endostatin produced in insect cells (Calbiochem) and in P. pastoris elicited comparable elevations of [Ca 2ϩ ] i in BAEC. Specificity of the endostatin response was also demonstrated immunologically. Preincubation of endostatin with neutralizing antibody reduced the endostatininduced increase in [Ca 2ϩ ] i from 179 Ϯ 41 nM (n ϭ 9) to 71 Ϯ 19 nM (n ϭ 6, P Ͻ 0.01). The antibodyinsensitive component of the endostatin-induced [Ca 2ϩ ] i increase approximated that elicited by antibody alone in BAEC (93 Ϯ 8 nM), but not in HEK-293 T cells (not shown), possibly reflecting activation of endothelial CD32/Fc-␥-RIIa (17) .
Although the angiogenic pathways activated by VEGF and FGF-2 differ in integrin specificity (15) (33) . Among the three defined VEGF receptors (VEGF-R1/flt1, VEGF-R2/KDR/flk1, and VEGF-R3/flt4) and the two coreceptors neuropilins 1 and 2, only VEGF-R2 (KDR/flk1) has been reported to elevate endothelial [Ca 2ϩ ] i in response to VEGF (7). KDR-mediated elevation of [Ca 2ϩ ] i has been attributed to IP 3 generation via src-dependent activation of PLC␥1. The requirement of KDR for IP 3 -mediated release of intracellular Ca 2ϩ stores may explain, at least in part, attenuation of VEGF-165-mediated Ca 2ϩ signaling by long-term endostatin exposure. This antagonistic effect is consistent with the ability of xestospongin C (Fig. 3) and U-73122 (Fig. 4) to inhibit acute [Ca 2ϩ ] i elevation by endostatin and consistent with the ability of acute endostatin treatment to deplete carbachol-and thapsigargin-sensitive Ca 2ϩ stores (Fig. 2) . Further studies will assess in greater detail the roles played by depletion of IP 3 -sensitive or other intracellular Ca 2ϩ stores and/or of antagonism of Ca 2ϩ -entry pathways in the attenuation of acute Ca 2ϩ signaling by VEGF-165 and Fig. 9 . Endostatin attenuates Ca 2ϩ signaling by growth factors. Representative [Ca 2ϩ ]i responses in fura 2-loaded BAEC preincubated for 20 h in the absence (top traces) or presence (bottom traces; arrow) of 2 g/ml endostatin. They were then acutely exposed to 30 ng/ml human vascular endothelial growth factor (VEGF)-165 (A) or to 25 ng/ml human fibroblast growth factor 2 (FGF-2; B). C: mean peak [Ca 2ϩ ]i values (numbers in parentheses indicate number of similar experiments). *P Ͻ 0.001 compared with absence of endostatin.
FGF-2 mediated by chronic endostatin exposure. These studies will be facilitated in turn by progress in defining additional intracellular signals triggered by both pro-and antiangiogenic agents.
[Ca 2ϩ ] i elevation in BAEC by extracellular endostatin and angiostatin suggests that Ca 2ϩ may serve as an intracellular messenger of plasmalemmal transmembrane receptors for each antiangiogenic polypeptide. The nature of these receptors (32) has been debated, 1 but intracellular signaling pathways are beginning to emerge. Angiostatin has been reported to diminish activation of ERK1 and ERK2 by bFGF and VEGF in human dermal microvascular endothelial cells, but not in bovine adrenal cortex capillary endothelial cells. Angiostatin has also been reported to activate focal adhesion kinase in several endothelial cell types by a pathway not inhibited by soluble RGD peptide (6) . Endostatin undergoes endocytosis and promotes tyrosine phosphorylation of the adaptor protein Shb, with promotion of protein complex formation (12) . In addition, preliminary experiments show that endostatin can rapidly mobilize from cytosol to nucleus a green fluorescent protein-tagged fusion construct of the Ca 2ϩ -dependent transcription factor NFAT1 (L. Jiang and S. L. Alper, unpublished observations).
The finding that endostatin and angiostatin acutely elevate endothelial cell [Ca 2ϩ ] i expands the intracellular signaling repertoire of these antiangiogenic agents and will contribute to the molecular characterization of their receptors. 1 An unusual candidate has been proposed as an angiostatin receptor, a ␤-subunit of the mitochondrial H ϩ -ATPase proposed to localize to the plasma membrane (32). The 1:10 dilution of crude antiserum to E. coli mitochondrial H ϩ -ATPase ␤-subunit that was shown to partially inhibit [
125 I]-labeled angiostatin binding to human umbilical vein endothelial cell monolayers (32) could not be tested as an antagonist of angiostatin-induced Ca 2ϩ signaling. Even at 1:100 dilution, the crude antiserum itself elicited large elevations in [Ca 2ϩ ]i in BAEC (data not shown).
